Presented June News Today

Two diabetes research giants, Ralph DeFronzo, MD, and David Nathan, MD, faced off on whether to use initial combination therapy versus starting with metformin and adding more medications sequentially.

Engraftment of Vertex Pharmaceuticals VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.

In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development.

Higher doses of oral semaglutide (25 mg and 50 mg) seem to be effective in type 2 diabetes and obesity, improving upon results obtained with currently approved maximum dose of oral semaglutide 14 mg daily.

Teenagers often set the alarms on their continuous glucose monitors to levels that cause needless distress, researchers found.

Maintaining hypercapnia for the first 24 hours in comatose patients resuscitated after out-of-hospital cardiac arrest did not improve outcomes in a large, randomized trial.

High-dose hemodiafiltration led to substantially better survival of patients with end-stage kidney disease compared with conventional hemodialysis after a median 30 months in a large, prospective study.

In the ongoing absence of a reliable biomarker for multiple sclerosis, misdiagnosis is a common, and persistent, problem that potentially puts patients at prolonged and unnecessary risk.

Less aggressive therapy may be appropriate for older adults with early breast cancer. Decisions should be made considering patient preferences and with the help of clinicians skilled at communicating.

Like a guardrail around a painting, oncologists can protect their well-being by fencing off their personal lives, setting boundaries, and saying no to unwanted tasks, various speakers told ASCO attendees.